2-Benzhydryloxyethyl(dimethyl)azanium;8-chloro-1,3-dimethyl-2-oxopurin-6-olate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Benzhydryloxyethyl(dimethyl)azanium;8-chloro-1,3-dimethyl-2-oxopurin-6-olate
• 化学式: C24H28ClN5O3
• 分子量: 470.0
• InChiKey: KKRAMGIVRBZVCD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.28
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  85
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] AMINOTHIOLESTER COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS AMINOTHIOLESTERS ET LEURS UTILISATIONS
  申请人：ADVANCED BIODESIGN

  公开号：WO2021019071A1

  公开（公告）日：2021-02-04

  The present invention relates to novel aminoesters compounds or its pharmaceutically acceptable salts or optical isomers, racemates, diastereoisomers, enantiomers or tautomers. The present invention also relates to their process of preparation and to these compounds for use as a medicament, in particular for the treatment or the prevention of cancer. The present invention further relates to an antibody drug conjugate comprising such compounds.

  本发明涉及新型氨基酯化合物或其药用可接受的盐或光学异构体、拉克酸盐、二对映异构体、对映体或互变异构体。本发明还涉及它们的制备方法以及这些化合物作为药物的用途，特别是用于治疗或预防癌症。本发明还涉及包含这些化合物的抗体药物结合物。
• PROCESS FOR PREPARING AMINOTHIOL ESTER COMPOUNDS AND SALTS THEREOF
  申请人：ADVANCED BIODESIGN

  公开号：US20190047948A1

  公开（公告）日：2019-02-14

  A process for preparing aminothiol ester compounds and salts thereof. The present invention relates to a process for preparing compounds of formula (I), (I) comprising the following steps: a) reacting a compound of formula (II) with an inorganic acid or an organic acid, (II) b) reacting the compound obtained in step a) with a base; c) reacting the compound obtained in step b) with CO 2 ; d) reacting the compound obtained in step c) with an alkyl chloroformate, a reagent capable of forming, with the compound obtained in step c), an acid halide, or a reagent capable of forming, with the compound obtained in step c), a mixed anhydride; e) reacting the compound obtained in step d) with an SMe anion precursor compound.

  制备氨硫醇酯化合物及其盐的方法。本发明涉及一种制备式(I)化合物的方法，(I)包括以下步骤：a)将式(II)化合物与无机酸或有机酸反应，(II) b)将步骤a)得到的化合物与碱反应；c)将步骤b)得到的化合物与CO2反应；d)将步骤c)得到的化合物与烷基氯甲酸酯、能够与步骤c)得到的化合物形成酸卤化物的试剂，或者能够与步骤c)得到的化合物形成混合酸酐的试剂反应；e)将步骤d)得到的化合物与SMe阴离子前体化合物反应。
• REMEDY FOR AUTOIMMUNE DISEASES
  申请人：KIRIN BEER KABUSHIKI KAISHA

  公开号：EP1676572A1

  公开（公告）日：2006-07-05

  In the present invention, there are disclosed a therapeutic agent for the treatment of a disease in which the suppression of Th1 cytokine production is therapeutically effective and/or a disease in which the suppression of autoantibody production is therapeutically effective, a therapeutic agent for the eradicative treatment of these diseases, and an agent for inhibiting the progress of these diseases, comprising (i) a proanthocyanidin with a polymerization degree of at least 4 or (ii) a plant material extract containing a proanthocyanidin as an active ingredient.

  在本发明中，揭示了一种治疗剂，用于治疗抑制Th1细胞因子产生在治疗上有效的疾病和/或抑制自身抗体产生在治疗上有效的疾病，一种用于根治这些疾病的治疗剂，以及一种用于抑制这些疾病进展的药剂，包括（i）至少为4的聚合度的原花青素或（ii）含有原花青素作为活性成分的植物材料提取物。
• Polymorphic forms of metopimazine
  申请人：Neurogastrx, Inc.

  公开号：US10836757B1

  公开（公告）日：2020-11-17

  Provided herein are novel polymorphic forms of metopimazine mesylate. These polymorphic forms are useful in methods, compositions, and kits for the treatment of an enteric nervous system disorder.

  本文提供了美托咪嗪甲磺酸盐的新型多形态形式。这些多形态形式在治疗肠道神经系统疾病的方法、组合物和试剂盒中是有用的。
• [EN] HETEROCYCLIC GLP-1 AGONISTS<br/>[FR] AGONISTES HÉTÉROCYCLIQUES DE GLP-1
  申请人：GASHERBRUM BIO INC

  公开号：WO2022052958A1

  公开（公告）日：2022-03-17

  This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

  本披露涉及公式(I)的GLP-1激动剂，包括其药学上可接受的盐和溶剂化物，以及包含它们的制药组合物。